Literature DB >> 15005279

Biologic premises of combined radiation therapy and chemotherapy in lung cancer.

Yuta Shibamoto1, Branislav Jeremic.   

Abstract

When radiation is combined with concurrent chemotherapy, independent cell kill and enhancement of tumor response may be expected. On the other hand, spatial cooperation may be the main rationale for sequential combination of the two modalities. Among many new agents being investigated, radiation-activated antitumor prodrugs have a therapeutic potential as a new method to effectively combine radiation and concurrent chemotherapy.

Entities:  

Mesh:

Year:  2004        PMID: 15005279     DOI: 10.1016/s0889-8588(03)00151-5

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  2 in total

1.  Chemoradiotherapy for localized extranodal natural killer/T-cell lymphoma, nasal type, using a shrinking-field radiation strategy: multi-institutional experience.

Authors:  Yukiko Hattori; Taro Murai; Hiromitsu Iwata; Kaoru Uchiyama; Mikio Mimura; Eriko Kato; Rumi Murata; Yuta Shibamoto
Journal:  Jpn J Radiol       Date:  2016-02-06       Impact factor: 2.374

2.  Intensity-modulated radiation therapy using static ports of tomotherapy (TomoDirect): comparison with the TomoHelical mode.

Authors:  Taro Murai; Yuta Shibamoto; Yoshihiko Manabe; Rumi Murata; Chikao Sugie; Akihiro Hayashi; Hiroya Ito; Yoshihito Miyoshi
Journal:  Radiat Oncol       Date:  2013-03-21       Impact factor: 3.481

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.